Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency.

Adenosine deaminase (ADA) deficiency and its biochemical consequences cause severe combined immunodeficiency (SCID). Treatment strategies, designed to correct the biochemical abnormalities, include transplantation of matched bone marrow or haploidentical bone marrow stem cells, repeated partial exchange transfusions with frozen irradiated human red blood cells (RBC), or weekly injection of polyethylene glycol-modified bovine ADA (PEG-ADA). To evaluate the effect of these therapeutic options, we studied in vitro T-cell function and in vivo antibody responses to the T-cell-dependent neoantigen, bacteriophage phi X174, in 10 children with ADA-deficient SCID. In untreated patients, T-cell function was severely depressed, and only minute amounts of antibacteriophage antibody were produced. Transplantation of bone marrow from a matched sibling (one patient) or a phenotypically matched parent (one patient) resulted in a stable graft, normal T-cell function, and substantial but subnormal antibody titers to bacteriophage, with reduced memory and impaired switch from IgM to IgG. Patients receiving T-cell-depleted haploidentical bone marrow stem cells had markedly depressed antibody responses for as long as 3 years posttransplantation, despite rapidly improving T-cell function that became normal in two of four patients. Two methods of enzyme replacement were explored. During treatment with human RBC transfusions, antibody responses to bacteriophage were as severely depressed as in untreated ADA-deficient patients. Treatment with weekly injections of PEG-ADA resulted in normalization of T-cell numbers in all four patients, normal or near-normal T-cell function in two, and mildly but variably improved T-cell function in the other two patients. Quantitatively and qualitatively normal antibody responses to bacteriophage were observed in three of four patients. Assessment of antibody responses to immunization with bacteriophage phi X174 is a useful method to monitor humoral immune function in treated ADA-deficient patients and can be used to estimate when intravenous immunoglobulin (IVIG) prophylaxis may be safely discontinued.

[1]  M. Hershfield,et al.  Enzyme Replacement Therapy with Polyethylene Glycol-Adenosine Deaminase in Adenosine Deaminase Deficiency: Overview and Case Reports of Three Patients, Including Two Now Receiving Gene Therapy , 1993, Pediatric Research.

[2]  J. Puck,et al.  Homozygosity for a newly identified missense mutation in a patient with very severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID). , 1991, American journal of human genetics.

[3]  R. Buckley,et al.  Donor type natural killer cells after haploidentical T cell-depleted bone marrow stem cell transplantation in a patient with adenosine deaminase-deficient severe combined immunodeficiency. , 1991, Clinical immunology and immunopathology.

[4]  A. Ammann,et al.  Interleukin 2 responsive lymphocytes in patients with adenosine deaminase deficiency. , 1989, Clinical immunology and immunopathology.

[5]  H. Ochs,et al.  Human antibody responses to bacteriophage phi X 174: sequential induction of IgM and IgG subclass antibody. , 1989, Clinical immunology and immunopathology.

[6]  M. Hershfield,et al.  Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. , 1988, The Journal of pediatrics.

[7]  M. Trigg,et al.  Reconstitution of T- and B-cell function after T-lymphocyte-depleted haploidentical bone marrow transplantation in severe combined immunodeficiency due to adenosine deaminase deficiency. , 1987, Clinical immunology and immunopathology.

[8]  S. Bigner,et al.  Identification of a deletion in the adenosine deaminase gene in a child with severe combined immunodeficiency. , 1987, Journal of immunology.

[9]  R. Kobayashi,et al.  Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. , 1987, The New England journal of medicine.

[10]  R. Hirschhorn.  Inherited enzyme deficiencies and immunodeficiency: adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) deficiencies. , 1986, Clinical immunology and immunopathology.

[11]  A. Huang,et al.  Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. , 1986, Journal of immunology.

[12]  R. Kobayashi,et al.  Iron overload as a result of transfusion therapy in a patient with adenosine deaminase deficiency. , 1985, The Nebraska medical journal.

[13]  F. Rosen,et al.  Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. , 1981, The Journal of clinical investigation.

[14]  R. Hirschhorn,et al.  Amelioration of Neurologic Abnormalities after Enzyme Replacement in Adenosine Deaminase Deficiency , 1980 .

[15]  M. Hershfield,et al.  In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients. , 1979, The Journal of clinical investigation.

[16]  R. A. Murphy,et al.  In vivo and in vitro effects of thymosin and adenosine deaminase on adenosine-deaminase-deficient lymphocytes. , 1979, The New England journal of medicine.

[17]  S. Chen,et al.  Adenosine deaminase deficiency: disappearance of adenine deoxynucleotides from a patient's erythrocytes after successful marrow transplantation. , 1978, The Journal of clinical investigation.

[18]  G. C. Mills,et al.  Limited effect of erythrocyte and plasma infusions in adenosine deaminase deficiency. , 1978, The Journal of pediatrics.

[19]  D. Martin,et al.  Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Stern,et al.  Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. , 1976, The New England journal of medicine.

[21]  E. Gelfand,et al.  Severe combined immunodeficiency and adenosine deaminase deficiency. , 1973, The New England journal of medicine.

[22]  H. Ochs,et al.  The recognition and classification of immunodeficiency diseases with bacteriophage phiChi 174. , 1975, Birth defects original article series.

[23]  E. Giblett,et al.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. , 1972, Lancet.

[24]  H. Ochs,et al.  Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. , 1971, The Journal of clinical investigation.

[25]  B. Swahn,et al.  Destruction of some agglutinins but not of others by two sulfhydryl compounds. , 2009, Acta pathologica et microbiologica Scandinavica.